(Q39662621)

13 September 2017

1 reference

title

Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia (English)

1 reference

13 September 2017

1 reference

1 reference

1 reference

J P Monk

1

1 reference

13 September 2017

P A Todd

series ordinal

2

1 reference

13 September 2017

language of work or name

1 reference

1 June 1987

1 reference

13 September 2017

1 reference

13 September 2017

volume

33

1 reference

13 September 2017

issue

6

1 reference

13 September 2017

page(s)

539-576

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-198733060-00002

13 September 2017

exact match

0 references

cites work

Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study

1 reference

12 December 2020

The effect of bezafibrate and clofibrate on cholesterol ester metabolism in 3T3 cells in smooth muscle cells in tissue culture

1 reference

12 December 2020

Pathogenesis and management of lipoprotein disorders

1 reference

12 December 2020

Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics

1 reference

12 December 2020

Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers

1 reference

12 December 2020

Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV

1 reference

12 December 2020

Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriocslerosis

1 reference

12 December 2020

The effect of bezafibrate and clofibrate on microsomal ACAT and lysosomal cholesterol ester hydrolase activity in the cholesterol-fed rabbit aorta

1 reference

12 December 2020

Effects of bezafibrate on low HDL-cholesterol in patients with ischaemic cerebrovascular disease: a pilot study

1 reference

12 December 2020

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

1 reference

12 December 2020

Pharmacokinetics of drugs in patients with the nephrotic syndrome

1 reference

12 December 2020

Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia

1 reference

12 December 2020

Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters

1 reference

12 December 2020

Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia

1 reference

12 December 2020

Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia

1 reference

12 December 2020

Double blind trial of bezafibrate in familial hypercholesterolaemia

1 reference

12 December 2020

[Bezafibrate and delayed action etofibrate in hyperlipidemia]

1 reference

12 December 2020

Double-blind cross-over study of the effect of sultosilic acid piperazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia

1 reference

12 December 2020

The effect of bezafibrate and clofibrate on cholesterol ester metabolism in rabbit peritoneal macrophages stimulated with acetylated low density lipoproteins

1 reference

12 December 2020

Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects

1 reference

12 December 2020

Classification of hyperlipidaemias and hyperlipoproteinaemias

1 reference

12 December 2020

Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia

1 reference

12 December 2020

Dose-effects studies with bezafibrate in patients with hypercholesterolemia and hypertriglyceridemia (author's transl)

1 reference

12 December 2020

Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.

1 reference

12 December 2020

The effect of bezofibrate and clofibrate on cholesterol accumulation, esterification and removal in cultured 3T3 fibroblasts

1 reference

12 December 2020

Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects

1 reference

12 December 2020

[Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia]

1 reference

12 December 2020

The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia

1 reference

12 December 2020

Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment

1 reference

12 December 2020

Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure

1 reference

12 December 2020

[Behavior of high-density lipoproteins in drug lipid-lowering treatment]

1 reference

12 December 2020

Lipid-lowering effect of bezafibrate in patients with diabetes mellitus and hyperlipidaemia (author's transl)

1 reference

12 December 2020

Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients

1 reference

12 December 2020

Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate

1 reference

12 December 2020

Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form

1 reference

12 December 2020

Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects

1 reference

12 December 2020

Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug

1 reference

12 December 2020

Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate

1 reference

12 December 2020

Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia

1 reference

12 December 2020

Effect of the hypolipidemic drug bezafibrate on the hepatic mixed function oxidase system of the rat: heterogeneity monooxygenase responses.

1 reference

12 December 2020

Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men

1 reference

12 December 2020

[Rhabdomyolysis with acute renal failure due to bezafibrate]

1 reference

12 December 2020

Treatment of uremic hypertriglyceridaemia with bezafibrate

1 reference

12 December 2020

Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. Normalization with bezafibrate therapy

1 reference

12 December 2020

Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects

1 reference

12 December 2020

The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia

1 reference

12 December 2020

[Bezafibrate in primary hyperlipidemias (author's transl)]

1 reference

12 December 2020

[Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function]

1 reference

12 December 2020

1 reference

12 December 2020

[Improvement in diabetes control by treatment with bezafibrate]

1 reference

12 December 2020

[Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate]

1 reference

12 December 2020

[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV]

1 reference

12 December 2020

Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.

1 reference

12 December 2020

Disposition pharmacokinetics of bezafibrate in man

1 reference

12 December 2020

Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats

1 reference

12 December 2020

Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liver

1 reference

12 December 2020

Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia

1 reference

12 December 2020

Specificity in the action of hypolipidemic drugs: increase of peroxisomal beta-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat

1 reference

12 December 2020

Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia

1 reference

12 December 2020

Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens

1 reference

12 December 2020

The effect of bezafibrate on the fibrinolytic enzyme system and the drug interaction with racemic phenprocoumon

1 reference

12 December 2020

Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteers.

1 reference

12 December 2020

Effect of bezafibrate on low levels of high density lipoprotein cholesterol in normolipidemia. Study in coronary patients and their first degree relatives

1 reference

12 December 2020

The somatostatin infusion test for the evaluation of glucose utilization in bezafibrate medication

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Statistical analysis of variations in total cholesterol, HDL, HDL2, HDL3, LDL-cholesterol, VLDL-triglycerides, apo-A and apo-B lipoproteins in dyslipidemias during antilipemic therapy

1 reference

12 December 2020

Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs

1 reference

12 December 2020

Clinical pharmacokinetics of bezafibrate in patients with impaired renal function

1 reference

12 December 2020

Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia.

1 reference

12 December 2020

Predominance of lactate dehydrogenase isoenzyme 1 in a patient with bezafibrate-induced rhabdomyolysis.

1 reference

12 December 2020

The short- and long-term effects of bezafibrate in the rat

1 reference

12 December 2020

Influence of bezafibrate on plasma lipoproteins, biliary lipids and fecal sterols in healthy men.

1 reference

12 December 2020

The effect of etofibrate retard, bezafibrate and procetofen

1 reference

12 December 2020

Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial.

1 reference

12 December 2020

The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study

1 reference

12 December 2020

10.2165/00003495-198733060-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

13 September 2017

1048221715

0 references

Fatcat ID

release_supkzm7ewbcsxebh5murlzjr7a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/supkzm7ewbcsxebh5murlzjr7a

24 November 2022

mapped directly with Wikidata item

1 reference